Vemurafenib and dabrafenib, two BRAF inhibitors, have significantly improved response rates (approximately 50%), progression-free survival (PFS) and better OS than chemotherapy in patients with metastatic BRAF V600E/K mutant melanoma [9,10]. The gene discussed is BRAF; the disease is melanoma.